Literature DB >> 8305923

Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients.

P G Vlachoyiannopoulos1, F B Karassa, K X Karakostas, A A Drosos, H M Moutsopoulos.   

Abstract

The purpose of this study was the descriptive analysis of patients with systemic lupus erythematosus (SLE) with a particular focus on initial clinical features, evolution and outcome of disease, prevalence of clinical and serological manifestations and identification of clinicoserological associations indicative of renal and CNS involvement. The methodology applied was the following: retrospective analysis of the clinical charts of 292 unselected patients (246 female (84.2%) and 46 male (15.7%)) with SLE examined between 1982 and 1992. Multivariate analysis and hierarchical log linear models were used to examine for clinicoserological associations. Descriptive analysis was based on the prevalence of main clinicoserological features and disease outcome. The outcome was examined on the basis of the number of flares, the presence of chronic renal failure, the presence of central nervous system (CNS) involvement with subsequent disability and deaths. Flares were considered the severe alterations in disease status, requiring additional therapy to be controlled. The disease begins most frequently in the second and third decade of life with cutaneous and joint manifestations, while renal and CNS involvement developed later. The prevalence of serious renal, pulmonary and CNS involvement as well as the prevalence of RF, anti-Sm and anti-nRNP antibodies remain low. Multivariate analysis revealed the associations of renal involvement with leukopenia and serositis, of anti-Sm with leukopenia, of secondary Sjogren's syndrome with RF and of thromboembolic events with anticardiolipin antibodies. Patients with childhood onset SLE have a higher tendency for developing renal involvement than adult onset SLE patients. In addition, anti-Ro(SSA) antibodies were associated with anti-La(SSB) and RF, while anti-Sm antibodies were associated with anti-nRNP and RF. Flares occurred with a frequency of 0.07 per patient per year. Only 63.6% of flares were accompanied by positive anti-dsDNA reactivities. Reported deaths were 0.0047 per patient per year. Hierarchical log linear models indicated that the main variables of the disease were sufficient to describe our disease model and that the order of the interaction between the variables was insignificant. We conclude that the prevalence of various clinical features associated with SLE is similar, although the prevalence of CNS and pulmonary involvement as well as anti-Sm and anti-nRNP antibodies are less prominent in Greek SLE patients than that reported in the literature. The various clinicoserological associations detected do not appear to be of major significance as they are not powerful enough to subgroup the disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8305923     DOI: 10.1177/096120339300200505

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  24 in total

1.  Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin.

Authors:  M Voulgarelis; S I Kokori; J P Ioannidis; A G Tzioufas; D Kyriaki; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

Review 2.  The initial presentation of systemic lupus erythematosis with aplastic anemia successfully treated with rituximab.

Authors:  Gholam-Hossein Alishiri; Amin Saburi; Noushin Bayat; Ali-Reza Saadat; Ehsan Saburi
Journal:  Clin Rheumatol       Date:  2011-10-21       Impact factor: 2.980

3.  Histopathological indicators of disease outcome in class IV lupus nephritis: a revisit of various indices.

Authors:  Manish Rathi; Krishan Lal Gupta; Kusum Joshi; Pramod K Gupta; Aman Sharma; Harbir Singh Kohli; Vivekanand Jha; Vinay Sakhuja
Journal:  Rheumatol Int       Date:  2015-03-11       Impact factor: 2.631

4.  Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case-control study from a single center.

Authors:  Melissa Padovan; Gabriella Castellino; Alessandra Bortoluzzi; Luisa Caniatti; Francesco Trotta; Marcello Govoni
Journal:  Rheumatol Int       Date:  2010-07-31       Impact factor: 2.631

Review 5.  Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment.

Authors:  S Giannouli; M Voulgarelis; P D Ziakas; A G Tzioufas
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

6.  Autoimmune thyroiditis and anti-thyroid antibodies in primary Sjogren's syndrome: a case-control study.

Authors:  R Tunc; M S Gonen; O Acbay; V Hamuryudan; H Yazici
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

7.  Decreased serum level of IL-21 in new-onset systemic lupus erythematosus patients.

Authors:  Hai-Feng Pan; Guo-Cui Wu; Yin-Guang Fan; Rui-Xue Leng; Hui Peng; Mo Zhou; Bao-Zhu Li; Yan Zhu; Jin-Hui Tao; Xiang-Pei Li; Dong-Qing Ye
Journal:  Rheumatol Int       Date:  2013-03-29       Impact factor: 2.631

8.  RNA recognition motif (RRM) of La/SSB: the bridge for interparticle spreading of autoimmune response to U1-RNP.

Authors:  John G Routsias; Nikolaos Kyriakidis; Michael Latreille; Athanasios G Tzioufas
Journal:  Mol Med       Date:  2009-10-14       Impact factor: 6.354

9.  Anticentromere antibody positive Sjögren's Syndrome: a retrospective descriptive analysis.

Authors:  Vasiliki-Kalliopi K Bournia; Konstantina D Diamanti; Panayiotis G Vlachoyiannopoulos; Haralampos M Moutsopoulos
Journal:  Arthritis Res Ther       Date:  2010-03-13       Impact factor: 5.156

10.  Visceral leishmaniasis resembling systemic lupus erythematosus.

Authors:  Michalis Voulgarelis; Paraskevi V Voulgari; John Serelis; Alexandros A Drosos; Fotini N Skopouli
Journal:  Clin Rheumatol       Date:  2003-10-31       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.